Neurocognitive correlates of apathy and anxiety in Parkinson's disease by Bogdanova, Y. & Cronin-Golomb, Alice
Boston University
OpenBU http://open.bu.edu
Psychological and Brain Sciences BU Open Access Articles
2011
Neurocognitive correlates of
apathy and anxiety in Parkinson's
disease
This work was made openly accessible by BU Faculty. Please share how this access benefits you.
Your story matters.
Version Published version
Citation (published version): Y Bogdanova, A Cronin-Golomb. 2011. "Neurocognitive correlates of
apathy and anxiety in Parkinson's disease." Parkinson’s Disease,
Volume 2012, https://doi.org/10.1155/2012/793076
https://hdl.handle.net/2144/34957
Boston University
Hindawi Publishing Corporation
Parkinson’s Disease
Volume 2012, Article ID 793076, 9 pages
doi:10.1155/2012/793076
Research Article
Neurocognitive Correlates of Apathy and Anxiety in Parkinson’s
Disease
Yelena Bogdanova1, 2, 3, 4 and Alice Cronin-Golomb1
1Department of Psychology, Boston University, Boston, MA 02215, USA
2Psychology Research (151-A), VA Boston Healthcare System, 150 South Huntington Street, Boston, MA 02130, USA
3Department of Psychiatry, Boston University School of Medicine, Boston, MA 02118, USA
4Department of Psychiatry, Harvard Medical School, Boston, MA 02115, USA
Correspondence should be addressed to Yelena Bogdanova, bogdanov@bu.edu and Alice Cronin-Golomb, alicecg@bu.edu
Received 31 July 2011; Accepted 25 October 2011
Academic Editor: Antonio Lucio Teixeira
Copyright © 2012 Y. Bogdanova and A. Cronin-Golomb. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Parkinson’s disease (PD) is associated with various nonmotor symptoms including neuropsychiatric and cognitive dysfunction.We
examined the relation between apathy, anxiety, side of onset of motor symptoms, and cognition in PD. We hypothesized that PD
patients would show different neuropsychiatric and neurocognitive profiles depending on the side of onset. 22 nondemented PD
patients (11 right-side onset (RPD) with predominant left-hemisphere pathology, and 11 LPD) and 22 matched healthy controls
(NC) were administered rating scales assessing apathy and anxiety, and a series of neuropsychological tests. PD patients showed
a higher anxiety level than NC. There was a significant association between apathy, anxiety, and disease duration. In LPD, apathy
but not anxiety was associated with performance on nonverbally mediated executive function and visuospatial measures, whereas,
in RPD, anxiety but not apathy correlated with performance on verbally mediated tasks. Our findings demonstrated a differential
association of apathy and anxiety to cognition in PD.
1. Introduction
Parkinson’s disease (PD) is a progressive neurodegenerative
disorder characterized by the loss of nigrostriatal and meso-
cortical dopaminergic projections from the brain stem and
limbic cortex to the basal ganglia and neocortex. The basal
ganglia and related structures are critical structures in para-
llel frontal subcortical circuits involved in regulation of cog-
nition, emotions, and behavioral activation [1–3]. While pri-
marily characterized as a movement disorder, PD is associat-
ed with various nonmotor symptoms [4–6], including cogni-
tive dysfunction [7–10] and neuropsychiatric symptoms,
such as apathy [11–17] and anxiety [18–20]. Recent neuro-
imaging and neuropsychological findings raise the question
of the role of apathy and anxiety in PD-related cognitive dys-
function, as these neuropsychiatric conditions reflect dys-
function in brain areas involved in PD.
Typically, early motor signs of PD start on one side of the
body, and side of onset remains a significant clinical and
neuropathological factor in both clinical management and
the study of PD. PD patients with symptoms starting on the
right side of the body (RPD) have greater inferred left hemi-
sphere pathology and those with left-side onset (LPD) have
greater inferred right hemisphere pathology [21]. The motor
symptoms of PD are associated with asymmetrical depletion
of dopamine in the substantia nigra of the midbrain across
the range of disease severity. These changes in the substantia
nigra lead to asymmetrical dysregulation of the striatum,
which may in turn lead to further asymmetrical dysfunction
of neural circuits including the basal ganglia and cortical pro-
jection areas (reviewed in [8]). This neuropathological asym-
metry remains evident even with PD progression [22], and
initial motor asymmetry predicts a range of motor and neu-
ropsychiatric deficits in PD patients [21, 23]. Specific cog-
nitive problems are also related to side of initial motor onset:
LPD versus RPD [8].
Cognitive impairments to a various degree have been
documented in many patients with PD. The most common
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cognitive domains affected are attention and executive fun-
ction (planning, problem solving, verbal fluency) and visu-
ospatial function. While language abilities remain generally
intact, mild naming deficits may be present in some patients
[24]. Previous work demonstrated that the degree of impair-
ment and specificity of cognitive domain affected by the dis-
ease is mediated by the side of initial motor onset, which is
presumably predetermined by asymmetrical dopamine de-
pletion in PD (reviewed in [8]). Thus, cognitive domains
predominantly subserved by the left hemisphere, such as
verbally mediated tasks of executive function and verbal
memory would be more affected in RPD than LPD, and vice
versa. For instance, RPD patients showed poorer verbal
memory performance than do those with LPD, who were
more impaired on visual memory [7].
Apathy, a reduction in self-initiated cognitive, emotional,
and behavioral activity, is a common clinical feature of pre-
frontal and basal ganglia lesions or dysfunctions [25]. Apathy
was documented following direct damage to the prefrontal
cortex [26–28]. It is also a common feature of frontostriatal
diseases, such as PD [11–14], Huntington’s disease [29–31],
and HIV [32–37]. Apathy in PD is attributed to nigrostriatal
dopaminergic loss in basal ganglia [38] and is considered
one of the core features of PD [17], occurring in up to 70%
of PD patients [39]. While apathy symptoms may overlap
with those of depression, the two conditions have been
shown to be reliably differentiated in patient samples [16,
40]. Apathy was related to cognitive dysfunction in PD and
other frontostriatal disorders. Specifically, apathy was associ-
ated with more severe cognitive dysfunction, specifically exe-
cutive dysfunction in PD [13, 14, 41]. Studies of HIV have
documented associations between the presence of apathy and
poor performance on measures of executive function, sug-
gesting that apathy and HIV-related cognitive dysfunction
may share common neurophysiological substrates [3, 42].
Apathy is more common in patients with right than left
hemisphere damage [14, 43]. Neuroimaging studies showed
that apathy was correlated with decreased right temporo-
parietal perfusion in Alzheimer’s patients [44] and with de-
creased gray matter volume in the right anterior cingulate
in older adults [45]. In PD, apathy was correlated with low
gray matter density in bilateral inferior frontal and inferior
parietal gyrus, right cingulate and right precuneus in one
study [46] and with low volume of the right medial temporal
lobe in another study [12].
Anxiety is also a very common and yet under studied
nonmotor symptom of PD. Prevalence of anxiety disorders
in PD varies, with estimates up to 49% [18, 47–49]. Previous
studies documented a negative impact of anxiety symptoms
on severity of PD [49], subjective motor symptoms [50] and
on health-related quality of life in PD [51, 52]. Anxiety also
may be associated with depression in PD. Some authors re-
ported overlapping symptoms of depression and anxiety in
PD patients [49]. However, dissociation of anxiety and de-
pression in PD was also documented by several studies [53].
Previous studies provide support to the notion that anxiety
and depression refer to different neural mechanisms in pa-
tients with PD (reviewed in [53]). Earlier studies reported
anxiety associated with various cognitive deficits [54–56],
though few studies have investigated the effect of anxiety on
cognition in PD. One study found that PD patients with sym-
ptoms of anxiety demonstrated poorer performance of vari-
ous measures of executive functioning, attention, processing
speed, and episodic memory [57]. These findings remained
significant after symptoms of depression were controlled.
Ryder and colleagues also reported a negative association bet-
ween anxiety and cognitive performance in PD [58]. Anxiety
is a common feature of left hemisphere involvement [59–61].
Lesion studies showed that individuals with left hemisphere
lesions may be particularly at risk of developing anxiety after
stroke [62]. Anxiety was also associated with greater left-
hemisphere activation in healthy adults [63]. More recently,
anxiety was associated with bilateral middle frontal, anterior
cingulate, and left parahippocampal/amygdala region in
healthy adults [64]. Another study of healthy adults that re-
ported left amygdala volumes significantly predicted anxiety
scores and found an overlap between areas associated with
both amygdala volume and anxiety scores in the orbitofron-
tal cortex and the left inferior parietal region [65]. Apathy
and anxiety both have a very significant effect on quality of
life and substantially increase patient disability [52, 66, 67].
Understanding their effect on cognition, elucidating under-
lying neural mechanisms and evaluating the implications for
management of these neuropsychiatric symptoms PD are
urgently needed.
This study aimed to further elucidate the phenomenol-
ogy of neuropsychiatric symptoms in PD by (1) assessing the
effect of neuropsychiatric status on cognitive function, in
particular, the relation of apathy, anxiety, and cognition; and
(2) relating them to the hemispheric asymmetry of initial
presentation (side of onset of motor symptoms). Previous
neuroimaging studies demonstrated that different neuropsy-
chiatric conditions are differentially mediated by lateralized
brain areas (as outlined above), which led us to expect that
the expression of apathy and anxiety in PD would be lateral-
ized as well. We hypothesized that PD patients would show
different neuropsychiatric and neurocognitive profiles de-
pending on the side of disease onset, with LPD exhibiting
cognitive deficits predominantly in the nonverbal domain,
which would be related to apathy, and RPD showing deficits
predominantly in verbal domain, which would be related to
anxiety. Apathy and anxiety are important determinants of
quality of life in PD. Early detection and treatment of both
conditions may enhance patients’ everyday functioning and
thus protect their quality of life.
2. Methods
2.1. Participants. The participants included 22 nondemented
individuals with PD and 22 normal control adults (NC), who
were matched on sociodemographic variables (see Table 1).
All participants scored 28 or higher on theMini-Mental State
Examination [68] and were not demented. Participants with
PD were recruited from the Parkinson Clinic of the Depart-
ment of Neurology, Boston Medical Center, and through
local support groups. Healthy age-matched control partici-
pants (NC) were recruited for the study from the community.
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Table 1: Demographic and clinical variables in PD and NC
participants. Means (SD) are reported unless otherwise indicated.
NC RPD LPD
N 22 11 11
Age 61.3 (6.9) 63.2 (6.0) 61.3 (6.2)
Years of Education 16.0 (1.9) 15.5 (2.2) 15.9 (3.0)
M : F 11 : 11 6 : 5 5 : 6
MMSE (total) 29.8 (0.5) 29.1 (0.9) 29.5 (0.8)
BDI-II (total) 4.6 (4.1)∗ 7.3 (3.5) 7.0 (4.0)
Disease Duration (Years) n/a 8.4 (3.7) 9.0 (4.0)
Hoehn and Yahr stage∧ n/a 2 (2-3) 2 (2-3)
LED n/a 475.2 (294.4) 497.5 (329.7)
BDI-II: Beck Depression Inventory-II.
∗ Significantly different from PD groups (Ps < 0.04).
∧Median (range).
n/a: not applicable.
LED: levodopa equivalent dosage.
The research was approved by Boston University’s Institu-
tional Review Board. Participants were required to be native
speakers of English. Exclusion criteria included coexisting
cancer, serious cardiac disease, other serious chronic medical
illness, prior intracranial surgery, history of traumatic brain
injury, psychiatric (not including diagnosis of depression or
anxiety) or neurological diagnoses other than PD, history
of alcoholism or other drug abuse, history of eye disease or
other visual abnormalities, and use of psychoactive medica-
tions, except for use of antidepressants and anxiolytics in the
PD group, which are commonly prescribed. PD clinical stag-
ing was determined by their neurologist based on the widely
used index of motor disability, Hoehn and Yahr scale [69]. All
PD participants were stages II-III (mild to moderate bilat-
eral). The average duration of disease was 8.7 years (SD =
3.8). PD diagnosis was made by patients’ neurologists, using
UK Parkinson’s Disease Society Brain Bank clinical diagnos-
tic criteria [70]. Side of motor symptom onset was obtained
by patient report as well as from the patient’s neurologist re-
cords. Eleven patients had right body side onset of motor
symptoms (RPD: 6 men, 5 women), and 11 had left-side
onset (LPD: 5 men, 6 women). RPD and LPD groups did not
differ in age, education, mental status, Hoehn and Yahr
stage, or disease duration. There were no group differences
between male and female PD participants in age, education,
mental status, Hoehn and Yahr stage, or disease duration. All
PD participants received daily dopamine replacement ther-
apy and/or dopamine receptor agonists. Levodopa equivalent
dosages (LED) were calculated based on previous reports
with LED: (regular levodopa dose× 1) + (levodopa controll-
ed-release dose× 0.75) + (pramipexole dose× 67.0) + (ropi-
nirole dose× 16.67) + (rotigotine× 16.67) + (pergolide dose
and cabergoline dose× 67.0) + (bromocriptine dose× 10) +
([regular levodopa dose + levodopa controlled-release dose
× 0.75]× 0.25) if taking tolcapone or entacapone [71]. There
were no significant differences in RPD versus LPD patient
groups in levodopa dose equivalents and dopamine agonists.
None of the PD participants were taking anticholinergic
medications, and three were taking some form of sleep medi-
cation. PD participants were tested while being administered
their antiparkinsonian medications (in their “on state”).
2.2. Procedure. Before participating, each individual provid-
ed informed consent in accordance with regulations of the
Boston University Institutional Review Board. All partic-
ipants were administered standardized measures of neu-
ropsychiatric functioning, and a series of neuropsychological
measures sensitive to PD-associated cognitive impairments.
Cognitive tests were chosen to assess a range of cognitive abil-
ities in verbal and nonverbal domains, to specify the role of
neuropsychiatric symptoms in cognitive functioning in non-
demented individuals with PD. All tests were administered
and scored according to standard procedures. Because the PD
and NC groups were matched on age, education, and
male : female ratio, we compared and reported raw scores for
all tests.
2.2.1. Neuropsychiatric Status Assessment. We assessed anxi-
ety and apathy using standardized self-report measures.
Apathy was assessed using the modified 14-item Apathy
Evaluation Scale (AES) [11, 72]. Items are rated on a 0-to-
3 Likert scale. Scores range from 0 to 42, with higher scores
indicative of more severe apathy level. Sample items include,
“Are you interested in learning new things?” and “Are you in-
different to things?” AES and its modified version were re-
ported to have excellent psychometric properties and have
been used in studies of Parkinson’s disease [11, 13] and other
frontostriatal disorders [3, 36, 73]. Total score was the de-
pendent measure.
The Beck Anxiety Inventory (BAI) [74] is a 21-item self-
report instrument that assesses the existence and severity of
symptoms of anxiety. There is a four-point scale for each
item ranging from 0 to 3. Total score in the range of 0–13 is
considered indicative of minimal or no depression, 14–19 is
mild, 20–28 is moderate, and 29–63 is severe [75]. The BAI
was reported to differentiate well between anxious and non-
anxious groups in a variety of clinical settings.
The Beck Depression Inventory, Second Edition (BDI-II)
[76], is a 21-item self-report instrument that assesses the
existence and severity of symptoms of depression as listed in
the American Psychiatric Association’s Diagnostic and Statis-
tical Manual of Mental Disorders, Fourth Edition (DSM-IV)
[77]. There is a four-point scale for each item ranging from
0 to 3. Total score in the range of 0–13 is considered indica-
tive of minimal or no depression, 14–19 is mild, 20–28 is
moderate, and 29–63 is severe.
2.2.2. Cognitive Functioning Assessment. The neuropsycho-
logical series included a number of tests that we expected to
be sensitive to frontostriatal and parietal dysfunction (atten-
tion, executive function, visuospatial ability) as well as tests
that we expected would elicit relatively unimpaired perfor-
mance in the nondemented PD group (naming abilities and
memory). The focus of interest was also on the dissociation
between the performance on the verbally and nonverbally
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mediated tasks, which would be most relevant for the associ-
ation between the side of onset and cognitive functioning in
nondemented persons with PD.
Verbal Domain
(i) Controlled Oral Word Association Test [78]. This is
a standardized test of verbal (phonemic) fluency, in
which participants were required to generate words
beginning with a particular letter (F, A, S). Total
number correct within a 60-s time period for each
condition was recorded.
(ii) Digit Span, Wechsler Memory Scale III [79], is a stan-
dardized measure of efficiency of attention (Forward
Span) and working memory (Backward Span) in ver-
bal domain [61]. The standard total score was used
for the group comparison.
(iii) Clock Reading Test [27]. The participants are asked
to identify and “read” the time shown on each of the
10 clocks presented on a standard paper. Total num-
ber of correct responses and time to completion is re-
corded.
(iv) The Boston Naming Test (BNT) [80] is a test of con-
frontation naming, in which the participant names
60 black and white line drawings of objects presented
one at a time. The total number correct was recorded.
(v) California Verbal Learning Test-II (CVLT-II) [81] is a
test of list-learning verbal memory. Immediate Recall,
Delayed Recall, and number of errors were recorded.
Nonverbal Domain
(i) Raven’s Coloured Progressive Matrices (RCPM) [82].
This is a standardized measure assessing visuospatial
skills and reasoning ability. The task is to choose one
of six possible completions of an incomplete pattern
matrix. Total score (the number correct out of 36
items) was recorded.
(ii) The Trail Making Test (TMT) [83] is a standardized
test of psychomotor speed and executive functioning.
Trails B subtest is a measure of combined visual
search, psychomotor speed, and cognitive flexibility,
assessing the ability to shift and maintain the res-
ponse set, where participants sequentially alternate
between alpha-numeric sequences (1-A-2-B, etc.).
Time to completion was used for the group compar-
isons.
(iii) Spatial Span, Wechsler Memory Scale III [79], is stan-
dardized measure of efficiency of attention and work-
ing memory (Backward Span) in nonverbal domain
[61]. The standard total score was used for the group
comparison.
(iv) Visual Symbol Search Test (VS) [84] provides a mea-
sure of visual scanning abilities and sustained atten-
tion. Participants search and cancel the target symbol
in the nonverbal array. Time to completion was used
for the group comparison.
(v) Rey-Osterrieth Complex Figure Test (ROCF) [85]. In
an assessment of visuospatial memory, participants
were asked to recall the abstract figure image by re-
drawing it immediately after copying (incidental) and
again after 25 minutes (delayed recall). We employed
the 36-point scoring system evaluating the presence
and accuracy of the 18 elements of the ROCF, and a
total score was recorded.
2.2.3. Statistical Analyses. To analyze differences between PD
and NC groups, independent samples t-tests (2-tailed) were
used. Pearson correlations were performed to examine asso-
ciations between apathy and anxiety ratings and neuropsy-
chological performance within the PD and NC groups sepa-
rately. Multiple regression analyses were performed to exam-
ine the relative contribution of neuropsychiatric and disease-
related variables to cognitive functioning in PD, using apathy
and anxiety total scores and disease duration as predictors,
and neuropsychological test scores as criterion variables.
Analyses of performance of men and women in both the PD
and NC groups revealed no significant differences in neuro-
psychological profile or mood ratings, and data were accord-
ingly collapsed across gender.
3. Results
This study used a within-subject design, with each partici-
pant receiving all assessments. The results are divided into
two sections: the first section presents findings regarding the
effects of PD on neuropsychiatric status and cognitive func-
tion; the second section relates neuropsychiatric status to
cognitive performance, and more specifically to the hemi-
spheric asymmetry of initial presentation (side of onset of
motor symptoms).
3.1. Effect of PD on Neuropsychiatric Status and
Cognitive Function
Apathy. Independent groups t-tests revealed that the PD par-
ticipants reported significantly more apathy symptoms than
the NC group (F(1, 43) = 0.53, P < 0.04). AES mean total
score was 8.4 (SD = 3.9) for PD and 6.3 (SD = 2.9) for NC.We
also conducted RPD and LPD subgroup comparisons that
revealed significant differences between the two PD sub-
groups (F(1, 21) = 0.11, P < 0.02), with RPDmean total AES
score = 10.42 (SD = 3.3) and LPD score = 6.9 (SD = 3.8).
Apathy ratings (AES total score) significantly correlated with
disease duration (years since onset) (r = 0.57, P < 0.016).
Anxiety. The PD group reported significantly more anxiety
symptoms than the NC group (F(1, 43) = 1.49, P < 0.03).
BAI mean total score was 9.3 (SD = 8.1) for PD and 4.9 (SD =
5.2) for NC. There was a significant association between an-
xiety (BAI total score) and disease duration (years since on-
set) (r = 0.58, P < 0.015). PD subgroup comparisons did not
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Table 2: Neuropsychological performance; raw score mean values (SD).
NC RPD LPD
Verbal Domain
FAS total 50.2 (16.3) 45.2 (14.4) 41.5 (7.5)∗
Digit span forward total 12.1 (2.2) 10.6 (1.9) 11.2 (1.8)
Digit span backward total 8.8 (2.6) 6.6 (2.8)∗ 6.8 (1.6)∗∗
Clock reading total 48.5 (18.8) 64.2 (15.3)∗ 62.5 (24.1)
BNT total correct 56.4 (3.2) 57.3 (3.5) 55.9 (5.1)
CVLT-II immediate recall total 11.4 (2.2) 11.7 (3.5) 11.3 (3.2)
CVLT-II delayed recall total 10.8 (2.8) 11.1 (3.5) 8.9 (3.7)
Nonverbal Domain
RCPM total 34.1 (2.1) 31.1 (4.3)∗∗ 31.8 (3.0)∗
TMT B time 66.8 (31.4) 86.8 (40.3) 99.3 (90.9)
Spatial span forward total 8.4 (1.7) 7.5 (1.9) 8.0 (1.1)
Spatial span backward total 7.8 (1.8) 7.2 (1.2) 7.3 (2.2)
VS search time 82.2 (21.7) 130.9 (45.2)∗∗ 137.2 (93.7)∗∗
ROCF immediate recall total 17.1 (6.5) 15.6 (7.3) 17.8 (7.0)
ROCF delayed recall total 17.9 (6.1) 15.3 (8.3) 17.0 (7.2)
Significantly different from NC group: ∗P < 0.03, ∗∗P < 0.007.
FAS: Controlled Oral Word Association Test (F, A, S),
BNT: Boston Naming Test,
CVLT-II: California Verbal Learning Test-II,
RCPM: Ravens Coloured Progressive Matrices,
ROCF: Rey-Osterrieth Complex Figure,
VS: Visual Symbol Search.
show significant difference between RPD and LPD on BAI
(P > 0.46).
Cognitive Performance. To examine whether the PD group
exhibited cognitive deficits compared to the NC group, we
conducted independent groups t-tests across neuropsycho-
logical assessments. The PD group performed more poorly
than the NC group on a number of tests. Significant group
differences were observed on verbally and nonverbally med-
iated measures of executive and visuospatial functioning (see
Table 2).
3.2. Relation between Neurocognitive and Neuropsychiatric
Status and Side of Onset. Further analyses revealed correla-
tions between neuropsychiatric (AES and BAI) and neuro-
psychological measures (Table 3). The cognitive differences
remained significant when controlling for apathy (all Ps <
0.042) and for anxiety (all Ps < 0.035). As predicted, we ob-
served a different pattern of performance by the two PD sub-
groups. In LPD, apathy but not anxiety was associated with
performance on non-verbally mediated executive function
and visuospatial measures [TMT B, Spatial Span, and Visual
Search], whereas in RPD, anxiety but not apathy significantly
correlated with performance on verbally mediated tasks
[BNT, CVLT, Clock Reading, and FAS] (Table 3).
4. Discussion
We examined the effect of PD on neuropsychiatric status and
its relation to side of onset of motor symptoms and cognition
Table 3: Correlations between RPD and LPD neuropsychological
performance and apathy (AES) and anxiety (BAI) ratings.
Apathy Anxiety
Verbal domain
RPD
FAS total correct ns −0.74∗
Clock reading total errors ns 0.84∗∗
Clock reading impulsive errors ns 0.89∗∗
BNT total correct ns −0.84∗∗
CVLT errors (intrusions) ns 0.89∗∗
Nonverbal domain
LPD
TMT B time 0.73∗ ns
TMT B errors 0.64∗ ns
Spatial span forward total −0.68∗ ns
Spatial span backward total −0.69∗ ns
VS search time 0.65∗ ns
VS search errors (omissions) 0.70∗ ns
∗P < 0.025; ∗∗P < 0.005.
TMT: Trail Making Test,
VS: Visual Symbol Search.
in nondemented individuals with PD. First, PD patients re-
ported significantly more apathy and anxiety symptoms than
the NC group. There were also PD-related changes in multi-
ple cognitive domains. The affected domains included atten-
tion, executive function, and visuospatial function, which is
reflective of frontostriatal and parietal dysfunction associated
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with PD. Second, the extent of apathy and anxiety significan-
tly correlated with performance on neuropsychological mea-
sures of attention, executive, and visuospatial function.
Third, we observed different neuropsychiatric and neurocog-
nitive profiles depending on the side of disease onset, in sup-
port of our hypothesis. Specifically, we had predicted that pa-
tients with LPD would exhibit cognitive deficits predomi-
nantly in the visuospatial domain, which would be related to
apathy. In contrast, RPD would show cognitive deficits in
verbal domain, which would be associated with anxiety sym-
ptoms.
To our knowledge, this is the first study to demonstrate
a differential association of apathy and anxiety to cognitive
dysfunction in PD, in relation to the side of onset of motor
symptoms.
Apathy and anxiety are common clinical features of PD,
and both are important predictors of everyday functioning
and quality of life. Previous neuroimaging and neuropsycho-
logical studies related these neuropsychiatric conditions to
PD-associated dysfunction. However, the role of apathy and
anxiety in cognitive dysfunction and their underlying neuro-
physiological substrates remain a subject of ongoing investi-
gation. Several studies related apathy to cognitive dysfunc-
tion in PD and other frontostriatal disorders (reviewed earl-
ier in this paper).While anxiety was also associated with vari-
ous cognitive deficits [54–56], there have been only a few
studies that investigated the effect of anxiety on cognition in
PD [58]. We assessed the effect of both apathy and anxiety on
cognitive function in PD; in particular, the relation of apathy
and anxiety to lateralized cognitive domains (verbal versus
visuospatial).
Consistent with previous literature, our PD patients re-
ported significantly more apathy and anxiety symptoms than
the NC group, implicating disruption of specific frontostri-
atal neural pathways. Also, as expected, we observed PD-re-
lated changes in multiple cognitive domains in our sample of
nondemented patients, including attention, executive func-
tion, and visuospatial function. These findings provide addi-
tional support to earlier work, which suggested that the high-
er prevalence of apathy and anxiety in PD, as compared to
general population, reflects PD-related dysfunction of fron-
tostriatal systems.
As suggested by previous research (reviewed above), var-
ious neuropsychiatric conditions are differentially mediated
by lateralized brain areas, which led us to hypothesize that the
expression of apathy and anxiety in PD also would be later-
alized. Specifically, we expected that PD patients would
show different neuropsychiatric and neurocognitive profiles
depending on the initial side of motor onset. We predicted
that LPD patients would exhibit cognitive deficits predomi-
nantly in the visuospatial domain, which would be related to
apathy. We also examined the potential mediating influence
of anxiety on cognitive performance in PD. Specifically, we
expected that RPD patients would show cognitive deficits
predominantly in the verbal domain, which would be related
to anxiety.
As predicted, we observed different neuropsychiatric and
neurocognitive profiles in our PD subgroups. Apathy and an-
xiety differentially correlated with performance on neuro-
psychological measures. The lateralized cognitive domain
(verbal versus visuospatial) was the mediating factor in this
paradigm. The observed dissociation between apathy and
anxiety and distinct cognitive domains suggested anatomi-
cally and functionally distinct neural substrates. Consistent
with our hypotheses, in LPD, apathy but not anxiety was
associated with performance on nonverbally mediated exe-
cutive function and visuospatial tasks. This finding is consis-
tent with earlier reports of apathy being related to right-
hemisphere dysfunction [12, 14, 43, 46]. In RPD, by contrast,
anxiety but not apathy significantly correlated with perfor-
mance on verbally mediated tasks. This finding provides
additional support to lesion studies and neuroimaging re-
ports relating anxiety to left-hemisphere dysfunction [59–
61, 63, 65]. Taken together, our results demonstrated a dif-
ferential association of apathy and anxiety with cognition in
PD.
In this study, we observed no significant differences bet-
ween the RPD and LPD subgroups in anxiety ratings, and
higher levels of apathy in the RPD group as compared to
LPD. The lack of group differences in anxiety level and high-
er rate of apathy in the RPD group may potentially reflect
variations in the degree of lateralized pathology within each
subgroup in our nondemented PD sample. Future investiga-
tions with larger patient samples and a wider range of dis-
ease duration and disease characteristics may shed light on
changes in the lateralization and expression of neuropsychi-
atric deficits across time, as PD-associated neuropathological
changes may become less lateralized with disease progres-
sion. Longitudinal studies are needed to address the effect of
the treatment of apathy and anxiety on cognitive function
and quality of life in PD.
Although limited by the size of our study sample, our
results nevertheless indicate a significant relation between
neuropsychiatric status and disease duration in nondement-
ed PD. We found that apathy and anxiety ratings were asso-
ciated with PD duration. The identification and treatment of
these neuropsychiatric conditions in patients with PD is
very important, as both apathy and anxiety have significant
impact on quality of life and substantially increase patient
disability [66, 67]. Apathy and anxiety are treatable condi-
tions, and timely screening and intervention may protect the
quality of life and reduce disability in individuals with PD.
In conclusion, this study examined the association bet-
ween neuropsychiatric symptoms and cognitive function in
non-demented individuals with PD. Our findings supported
the notion that the higher rate of apathy and anxiety in PD
than in the general population may reflect a direct conseq-
uence of the damage to the frontostriatal system and its cor-
tical connections, resulting in both neuropsychiatric and
neurocognitive deficits. Examination of the relation between
apathy and anxiety and distinct cognitive domains suggested
anatomically and functionally distinct neural substrates. The
observed dissociation between RPD and LPD neuropsychia-
tric status and cognitive performance also points to distinct
underlying neural substrates within corticostriatal-thalamo-
cortical circuits. These results indicate specific relations of
apathy and anxiety to cognition in PD. Finally, we found that
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apathy and anxiety ratings were associated with disease dura-
tion. The results of this study stress the importance of iden-
tifying and treating these neuropsychiatric conditions in PD
patients.
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